ABSTRACT
120 patients with chronic gastritis and primary chronic gastroduodenitis were given a three-week course of etiopathogenetic treatment (antichelibacterial and immunocorrective drugs) that allowed to diminish the clinical, bacteriological and immune manifestations of the disease and achieve a complete cure in most patients. Patients with marked chelibacteriosis revealed greater refractoriness. The authors recommend prolonged courses of treatment with alternations of etiologically directed drugs.
Subject(s)
Duodenitis/drug therapy , Gastritis/drug therapy , Adjuvants, Immunologic/therapeutic use , Adolescent , Adult , Anti-Bacterial Agents/therapeutic use , Antibodies, Bacterial/blood , Autoimmune Diseases/complications , Autoimmune Diseases/diagnosis , Autoimmune Diseases/drug therapy , Chronic Disease , Drug Therapy, Combination , Duodenitis/diagnosis , Duodenitis/etiology , Female , Gastritis/diagnosis , Gastritis/etiology , Helicobacter Infections/complications , Helicobacter Infections/diagnosis , Helicobacter Infections/drug therapy , Helicobacter pylori/immunology , Humans , Male , Middle AgedABSTRACT
Organ antibodies were studied after immunothermistometry treatment in 205 patients with chronic diseases of the liver. One group of patients was treated by routine methods in accordance with the diagnosis, while the second group of patients was additionally given hemodes. Before treatment organ antibodies were revealed in 31 patients (70.4%) with liver cirrhosis, in 44 (55%) with chronic hepatitis and 45 (55.5%) in chronic pancreatitis. After treatment these were respectively 9 (20.5%), 15 (18.7%) and 15 (18.5%). Depending on the treatment antibodies were more frequently eliminated in the first group of patients in chronic hepatitis. In liver cirrhosis and chronic pancreatitis there was no significant difference between the two groups of patients.